



Docket No.: PF-0027 US

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on October 7, 2002.

By [Signature]

Printed: Lyza Finuliar

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Coleman et al.

Title: NEW CHEMOKINE EXPRESSED IN PANCREAS

Serial No.: 08/390,740

Filing Date: February 17, 1995

Examiner: Marschel, A.

Group Art Unit: 1631

Commissioner for Patents
Washington, D.C. 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
WITH FEE UNDER §1.17(p)**

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

In view of the status of the subject application, pursuant to 37 CFR §1.97(c), Applicants hereby request consideration of this Information Disclosure Statement with accompaniment of a fee under 37 C.F.R. §1.17(p).

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant

100362

1

08/390,740

10/10/2002 NROCHA1 00000086 090108 08390740

02 FC:126

180.00 CH

#34
Plunkett
10/10/02

Docket No.: PF-0027 US

and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

For the Examiner's convenience, the attached 1449 papers and accompanying references are divided into two groups. The first group (marked PANEC-1 on the top of the 1449) includes references related to the polynucleotide of SEQ ID NO:1 and the polypeptide of SEQ ID NO:2 (i.e., PANEC-1), and the second group (marked PANEC-2 on the top of the 1449) contains references related to the polynucleotide of SEQ ID NO:3 and the polypeptide of SEQ ID NO:4 (i.e., PANEC-2). Also for the Examiner's convenience, a sequence alignment is attached to each reference to facilitate examination of the sequences disclosed in the reference as compared with the claimed sequence. Please note that the vast majority of these references are not believed to be prior art, but rather are either published or filed (patent references) within two years of the filing date of the instant application. Accordingly, these references are cited in an abundance of caution, or are cited to further demonstrate that Applicants' invention clearly possesses the important properties disclosed in the application.

Please charge the Petition fee of **\$180.00** under 37 C.F.R. §1.17(p) to Deposit Account No. **09-0108**. The Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

Docket No.: PF-0027 US

If there are any questions regarding the above, the Examiner is invited to call the undersigned at (650) 855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date:

7 Oct 2002



Diana Hamlet-Cox

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166